Fig. 2
From: Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
Mean and 95% CI of vaccine efficacy estimates with and without imputations for subjects with baseline seronegative, monotypic and multitypic PRNT50 titre profiles. Estimates were obtained from 1000 realisations of the final BRT model achieving at least 30% accuracy for cases and non-cases, trained on 75% of non-cases and 75% of cases and using five-fold cross-validation, tc = 15, lr = 0.001, bf = 0.75. a Proportion of correct classifications among seronegative (sero−), monotypic (mono), multitypic (multi) and overall (i.e. seronegative, monotypic and multitypic) cases, non-cases and overall (cases and non-cases). b Vaccine efficacy estimates for baseline multitypic, monotypic and seronegative subjects separately. c Vaccine efficacy estimates for baseline multitypic, monotypic and seronegative subjects by age, using 2–8, 9–11, 12–16 and 9–16 years age-groups. d Vaccine efficacy estimates by serotype for baseline multitypic, monotypic and seronegative subjects over all ages (2–16 years). e Vaccine efficacy estimates by serotype for baseline multitypic, monotypic and seronegative subjects 2–8 years old. f Vaccine efficacy by serotype for baseline multitypic, monotypic and seronegative subjects 9–16 years old
